Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.

Ghouri N, Preiss D, Sattar N.

Hepatology. 2010 Sep;52(3):1156-61. doi: 10.1002/hep.23789. Review.

PMID:
20658466
2.

Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A.

J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264. Review.

PMID:
26667191
3.

Perspective: nonalcoholic fatty liver disease and cardiovascular risk.

Nestel PJ, Mensink RP.

Curr Opin Lipidol. 2013 Feb;24(1):1-3. doi: 10.1097/MOL.0b013e32835c0834.

PMID:
23298957
4.

Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Williams KH, Sullivan DR, Nicholson GC, George J, Jenkins AJ, Januszewski AS, Gebski VJ, Manning P, Tan YM, Donoghoe MW, Ehnholm C, Young S, O'Brien R, Buizen L, Twigg SM, Keech AC.

Metabolism. 2016 May;65(5):783-93. doi: 10.1016/j.metabol.2015.12.008. Epub 2015 Dec 21.

PMID:
27085785
5.

Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study.

Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, Buiatti E, Rotella CM, Mannucci E.

Metabolism. 2008 Mar;57(3):387-92. doi: 10.1016/j.metabol.2007.10.015.

PMID:
18249212
6.

Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa Heart Study.

Nguyen QM, Srinivasan SR, Xu JH, Chen W, Hassig S, Rice J, Berenson GS.

Diabetes Care. 2011 Dec;34(12):2603-7. doi: 10.2337/dc11-0919. Epub 2011 Sep 27.

7.

Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies.

Kunutsor SK, Apekey TA, Khan H.

Atherosclerosis. 2014 Sep;236(1):7-17. doi: 10.1016/j.atherosclerosis.2014.06.006. Epub 2014 Jun 23. Review.

PMID:
24998934
8.

γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.

Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN, Strachan MW, Price JF.

Diabetologia. 2015 Jul;58(7):1484-93. doi: 10.1007/s00125-015-3575-y. Epub 2015 Mar 29.

9.

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.

Mantovani A, Mingolla L, Rigolon R, Pichiri I, Cavalieri V, Zoppini G, Lippi G, Bonora E, Targher G.

Int J Cardiol. 2016 Dec 15;225:387-391. doi: 10.1016/j.ijcard.2016.10.040. Epub 2016 Oct 17.

PMID:
27768965
10.

Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.

Stepanova M, Younossi ZM.

Clin Gastroenterol Hepatol. 2012 Jun;10(6):646-50. doi: 10.1016/j.cgh.2011.12.039. Epub 2012 Jan 13.

PMID:
22245962
11.

Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study.

Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Blokzijl H, Gansevoort RT, Dullaart RP.

Atherosclerosis. 2015 Nov;243(1):138-47. doi: 10.1016/j.atherosclerosis.2015.09.006. Epub 2015 Sep 8.

PMID:
26386210
12.

Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients.

Zelle DM, Corpeleijn E, van Ree RM, Stolk RP, van der Veer E, Gans RO, Homan van der Heide JJ, Navis G, Bakker SJ.

Am J Transplant. 2010 Jan;10(1):106-14. doi: 10.1111/j.1600-6143.2009.02876.x. Epub 2009 Nov 24.

13.

Liver enzymes: potential cardiovascular risk markers?

Lioudaki E, Ganotakis ES, Mikhailidis DP.

Curr Pharm Des. 2011 Nov;17(33):3632-43. Review.

PMID:
22074433
14.

Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.

Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ.

Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):437-43. Review.

PMID:
16832839
15.
16.

Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis.

Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA.

Diabetes Care. 2009 Apr;32(4):741-50. doi: 10.2337/dc08-1870. Epub 2009 Jan 8.

17.
18.

Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study.

Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, Oh KW, Park SW, Lee WY.

Arch Med Res. 2013 Feb;44(2):115-20. doi: 10.1016/j.arcmed.2013.01.007. Epub 2013 Feb 8.

PMID:
23398788
19.

The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes.

Wannamethee SG, Lennon L, Shaper AG.

Atherosclerosis. 2008 Nov;201(1):168-75. doi: 10.1016/j.atherosclerosis.2008.01.019. Epub 2008 Mar 10.

PMID:
18378241
20.

The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects.

Sung KC, Ryan MC, Wilson AM.

Atherosclerosis. 2009 Apr;203(2):581-6. doi: 10.1016/j.atherosclerosis.2008.07.024. Epub 2008 Jul 31.

PMID:
18774133

Supplemental Content

Support Center